[Federal Register: September 20, 2002 (Volume 67, Number 183)]
[Notices]
[Page 59295-59296]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr20se02-94]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by agencies of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
New Tumor Suppressor Gene, p28ING5
Dr. Curtis C. Harris et al. (NCI)
DHHS Reference No. E-300-01/0 filed January 23, 2001
Licensing Contact: Catherine Joyce; 301/496-7735 ext. 258; e-mail:
joycec@od.nih.gov
This technology pertains to the discovery of a new member of the
ING (inhibitor growth) family of putative tumor suppressor genes,
p28ING5. p28ING5 was identified by homology to the tumor suppressor
gene p33ING1. Over-expression of the ING5 protein causes cell cycle
arrest in human cancer cell lines and ING5 expression varies between
cancer cell lines. Detection of ING5 gene or protein expression could
potentially be used for cancer diagnosis and ING5 could be used as a
medicant.
The above-mentioned invention is available for licensing on an
exclusive or non-exclusive basis.
HGC-1, A Gene Encoding a Member of the Olfactomedin-Related Protein
Family
Griffin P. Rodgers, Wen-Li Liu, Jiachang Zhang (NIDDK)
U.S. Provisional Patent Application 60/338,759 (E-166-01/0) filed
December 7, 2001
Licensing Contact: Brenda Hefti; 301/496-7736 ext. 206; e-mail:
heftib@od.nih.gov
The current technology embodies a newly identified gene, Human
Granulocyte Colony-Stimulating Factor-Stimulated-Clone-1 (hGC-1) that
has been cloned and characterized, and its protein sequence has been
deduced. The gene is expressed in the bone marrow, prostate, small
intestine, colon, and stomach, and has been mapped to chromosome 13 in
a region that contains a tumor suppressor gene cluster. The gene is
found to be selectively present in normal human myeloid lineage cells
and is believed to play a role in allowing lymphocytes to differentiate
properly. It is believed that the gene may be used as a selective
marker for human prostate cancer, multiple myeloma, B-cell chronic
lymphocytic leukemia and other types of cancer and can be used
diagnostically as well as in therapeutic screening activities.
Modulating IL-13 Activity Using Mutated Il-13 Molecules That Are
Antagonists or Agonists of IL-13
R. Puri, Y. Oshima, and B. Joshi (FDA)
PCT Application PCT/US00/31044 (E-032-00/2) filed November 10, 2000,
and claiming priority to a U.S. Provisional application filed November
11, 1999
Licensing Contact: Brenda Hefti; 301/496-7736 ext. 206; e-mail:
heftib@od.nih.gov
The present invention provides antagonists and agonists of IL-13
activity. The antagonists can be used to reduce or end symptoms in
conditions, such as asthma, allergic rhinitis, atopic dermatitis,
parasitic infections, pulmonary fibrosis, and others in which
[[Page 59296]]
IL-13 is an initiator, mediator or enhancer of the abnormal state. The
agonists can also be used as reagents in the maturation of monocytes
into dendritic cells, or to pre-treat bone marrow stem cell donors to
reduce GVH disease. The antagonists can be used to slow the growth of
cells in cancers for which IL-13 is an autocrine growth factor.
This invention also claims IL-13 receptor binding molecules with
affinity for the IL-13 receptor at least three times greater than that
exhibited by wild type IL-13. Finally, this invention claims methods
and compositions for specifically delivering an effector molecule to a
tumor cell by chimeric molecules comprising the effector molecule
(plant or bacterial toxin, chemotherapeutic agents or antibiotics) and
an IL-13 receptor binding molecule (antagonists or agonists), and
pharmaceutical compositions thereof.
Dated: September 12, 2002.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 02-23875 Filed 9-19-02; 8:45 am]
BILLING CODE 4140-01-P